Actinium Pharmaceuticals, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sandesh C. Seth
- Full Time Employees
- 31
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 275 Madison Avenue New York City NY United States of America 10016
- IPO Date
- Dec 27, 2012
- CIK
- 0001388320
- Website
- actiniumpharma.com
- Similar Companies
- Business
- Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to the advancement and commercialization of precision oncology treatments, including those for bone marrow transplantation, cell and gene therapies, and various adoptive cell approaches. Its leading therapeutic candidate, Iomab-B (I-131 apamistamab), an induction and conditioning agent for transplant, demonstrated positive primary endpoint results in the pivotal Phase 3 SIERRA trial for older patients with relapsed or refractory acute myeloid leukemia; however, the U.S. FDA has since requested further data demonstrating an overall survival benefit in an additional randomized clinical trial for Biologics License Application submission in the U.S.. Actinium is also advancing Actimab-A, a CD33-targeted therapeutic leveraging the alpha-emitter Actinium-225, positioned as a potential foundational therapy for acute myeloid leukemia and other myeloid conditions, with a pivotal Phase 2/3 study underway and additional research collaborations, including with Memorial Sloan Kettering Cancer Center, exploring novel combinations. The company's pipeline further encompasses ATNM-400, a first-in-class Actinium-225 radiotherapy targeting non-PSMA receptors for solid tumors like prostate, breast, and lung cancers, which has shown compelling preclinical efficacy. Other programs utilize diverse radioisotopes, such as Actinium-225 and Iodine-131, for targeted conditioning in cellular and gene therapies, exemplified by Iomab-ACT, and as standalone cancer treatments or in combination regimens. Actinium also distinguishes itself with proprietary cyclotron-based manufacturing technology for Actinium-225, aiming to establish a scalable and cost-effective supply of this critical isotope. Strategic alliances include a licensing agreement with Immedica Pharma AB for Iomab-B commercialization in Europe, the Middle East, and North Africa. Incorporated in 2000, the company maintains its headquarters in New York, New York.
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
Actinium Pharmaceuticals (NYSE:ATNM) vs. Comera Life Sciences (NASDAQ:CMRA) Critical Comparison
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
Reviewing Actinium Pharmaceuticals (NYSE:ATNM) & Aadi Bioscience (NASDAQ:AADI)
Actinium Pharmaceuticals (NYSE:ATNM) & ProMetic Life Sciences (OTCMKTS:PFSCF) Head to Head Comparison
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025
Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 0.7% – Here’s Why